Previous FDA winner on new surgical device. Puked after popping now stable. Could see run into earnings here up to 3.70 per share. Note that $50m financing deal is ongoing but this shouldn't have huge impact in the short term.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
